FOXC1 Promotes Melanoma by Activating MST1R/PI3K/AKT

Overview

Journal Oncotarget

Specialty Oncology

Date 2016 Aug 18

PMID 27533251

Citations 29

Authors

Jinhua Wang

Li Li

Shiwei Liu

Ying Zhao

Lin Wang

Guanhua Du

Affiliations

Soon will be listed here.

Abstract

FOXC1 is a member of Forkhead box family transcription factors. We showed that FOXC1 level was increased in melanoma cells and tissues and correlated with hypomethylation of the FOXC1 gene. Overexpression of FOXC1 promoted proliferation, migration, invasion, colony formation and growth in 3D Matrigel of melanoma cells. FOXC1 increased MST1R and activated the PI3K/AKT pathway. Also, FOXC1 expression was associated with disease progression and poor prognosis of melanoma. We suggest that FOXC1 is a potential prognostic biomarker for treating melanoma and predicting outcome of patients.

Citing Articles

Network-based analysis of heterogeneous patient-matched brain and extracranial melanoma metastasis pairs reveals three homogeneous subgroups.

Grutzmann K, Kraft T, Meinhardt M, Meier F, Westphal D, Seifert M Comput Struct Biotechnol J. 2024; 23:1036-1050.

PMID: 38464935 PMC: 10920107. DOI: 10.1016/j.csbj.2024.02.013.

Asymmetric and parallel subgenome selection co-shape common carp domestication.

Wang M, Li X, Wang C, Zou M, Yang J, Li X BMC Biol. 2024; 22(1):4.

PMID: 38166816 PMC: 10762839. DOI: 10.1186/s12915-023-01806-9.

Tepotinib suppresses proliferation, invasion, migration, and promotes apoptosis of melanoma cells via inhibiting MET and PI3K/AKT signaling pathways.

Jing G, Yu F, Xue H Oncol Lett. 2022; 23(6):170.

PMID: 35497936 PMC: 9019857. DOI: 10.3892/ol.2022.13290.

Drugging the Epigenome: Overcoming Resistance to Targeted and Immunotherapies in Melanoma.

Hanly A, Gibson F, Nocco S, Rogers S, Wu M, Alani R JID Innov. 2022; 2(2):100090.

PMID: 35199090 PMC: 8844701. DOI: 10.1016/j.xjidi.2021.100090.

Sinomenine ester derivative inhibits glioblastoma by inducing mitochondria-dependent apoptosis and autophagy by PI3K/AKT/mTOR and AMPK/mTOR pathway.

Zheng X, Li W, Xu H, Liu J, Ren L, Yang Y Acta Pharm Sin B. 2021; 11(11):3465-3480.

PMID: 34900530 PMC: 8642618. DOI: 10.1016/j.apsb.2021.05.027.

References

Camp R, Neumeister V, Rimm D . A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J Clin Oncol. 2008; 26(34):5630-7. DOI: 10.1200/JCO.2008.17.3567. View

Myatt S, Lam E . The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer. 2007; 7(11):847-59. DOI: 10.1038/nrc2223. View

Wang J, Chong K, Nakamura Y, Nguyen L, Huang S, Kuo C . B7-H3 associated with tumor progression and epigenetic regulatory activity in cutaneous melanoma. J Invest Dermatol. 2013; 133(8):2050-8. PMC: 3760237. DOI: 10.1038/jid.2013.114. View

Sundstrom T, Daphu I, Wendelbo I, Hodneland E, Lundervold A, Immervoll H . Automated tracking of nanoparticle-labeled melanoma cells improves the predictive power of a brain metastasis model. Cancer Res. 2013; 73(8):2445-56. DOI: 10.1158/0008-5472.CAN-12-3514. View

Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg S . TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 2013; 14(4):R36. PMC: 4053844. DOI: 10.1186/gb-2013-14-4-r36. View

Wagh P, Gray J, Zinser G, Vasiliauskas J, James L, Monga S . β-Catenin is required for Ron receptor-induced mammary tumorigenesis. Oncogene. 2011; 30(34):3694-704. PMC: 3134560. DOI: 10.1038/onc.2011.86. View

Feres K, Ischenko I, Hayman M . The RON receptor tyrosine kinase promotes MSP-independent cell spreading and survival in breast epithelial cells. Oncogene. 2008; 28(2):279-88. PMC: 2628450. DOI: 10.1038/onc.2008.383. View

Wei L, Zhou R, Xu H, Wang J, Yuan M . High expression of FOXC1 is associated with poor clinical outcome in non-small cell lung cancer patients. Tumour Biol. 2012; 34(2):941-6. DOI: 10.1007/s13277-012-0629-3. View

Wang J, Goetsch L, Tucker L, Zhang Q, Gonzalez A, Vaidya K . Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification. BMC Cancer. 2016; 16:105. PMC: 4755020. DOI: 10.1186/s12885-016-2138-z. View

10.

Xia L, Huang W, Tian D, Zhu H, Qi X, Chen Z . Overexpression of forkhead box C1 promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma. Hepatology. 2012; 57(2):610-24. DOI: 10.1002/hep.26029. View

11.

Nilsson G, Kannius-Janson M . Forkhead Box F1 promotes breast cancer cell migration by upregulating lysyl oxidase and suppressing Smad2/3 signaling. BMC Cancer. 2016; 16:142. PMC: 4763409. DOI: 10.1186/s12885-016-2196-2. View

12.

Hamurcu Z, Ashour A, Kahraman N, Ozpolat B . FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells. Oncotarget. 2016; 7(13):16619-35. PMC: 4941339. DOI: 10.18632/oncotarget.7672. View

13.

Ray P, Wang J, Qu Y, Sim M, Shamonki J, Bagaria S . FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer. Cancer Res. 2010; 70(10):3870-6. DOI: 10.1158/0008-5472.CAN-09-4120. View

14.

Bloushtain-Qimron N, Yao J, Snyder E, Shipitsin M, Campbell L, Mani S . Cell type-specific DNA methylation patterns in the human breast. Proc Natl Acad Sci U S A. 2008; 105(37):14076-81. PMC: 2532972. DOI: 10.1073/pnas.0805206105. View

15.

Thang N, Yajima I, Kumasaka M, Iida M, Suzuki T, Kato M . Deltex-3-like (DTX3L) stimulates metastasis of melanoma through FAK/PI3K/AKT but not MEK/ERK pathway. Oncotarget. 2015; 6(16):14290-9. PMC: 4546467. DOI: 10.18632/oncotarget.3742. View

16.

Song Y, Washington M, Crawford H . Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer. Cancer Res. 2010; 70(5):2115-25. PMC: 2831111. DOI: 10.1158/0008-5472.CAN-09-2979. View

17.

Torti D, Trusolino L . Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. EMBO Mol Med. 2011; 3(11):623-36. PMC: 3377106. DOI: 10.1002/emmm.201100176. View

18.

Pyo J, Kang G, Kim D, Chae S, Park C, Kim K . Activation of nuclear factor-κB contributes to growth and aggressiveness of papillary thyroid carcinoma. Pathol Res Pract. 2013; 209(4):228-32. DOI: 10.1016/j.prp.2013.02.004. View

19.

Kuehl W, Bergsagel P . MYC addiction: a potential therapeutic target in MM. Blood. 2012; 120(12):2351-2. DOI: 10.1182/blood-2012-08-445262. View

20.

Wang J, Hua W, Huang S, Fan K, Takeshima L, Mao Y . RASSF8 regulates progression of cutaneous melanoma through nuclear factor-κb. Oncotarget. 2015; 6(30):30165-77. PMC: 4745788. DOI: 10.18632/oncotarget.5030. View